Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04924608 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas
A Phase 3 study of Neurofibromatosis 1 and Plexiform Neurofibroma (PN), sponsored by AstraZeneca.
- Active
- Registry status
- Phase 3
- Development phase
- 145
- Enrollment target
- 20
- Study locations
NCT04924608 is a Phase 3 study of Neurofibromatosis 1 and Plexiform Neurofibroma (PN) that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 145 participants, below the 1,029-participant average among 24 other Neurofibromatosis 1 trials with a reported enrollment target (86% lower). The trial reports 20 study locations across 7 states.
The verdict
NCT04924608, a Phase 3 study of Neurofibromatosis 1 and Plexiform Neurofibroma (PN), is active but no longer recruiting, sponsored by AstraZeneca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 145 participants
- Enrollment target
- 20
- Study locations
Study Summary
A global study to demonstrate the effectiveness of selumetinib in participants with NF1 who have symptomatic, inoperable plexiform neurofibromas.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Selumetinib
Study Locations (20)
Other
- Research Site - Melbourne
- Research Site - St Leonards
- Research Site - Porto Alegre
- Research Site - Ribeirão Preto
- Research Site - São Paulo
- Research Site - Beijing
- Research Site - Beijing
- Research Site - Guangzhou
- Research Site - Shenyang
- Research Site - Créteil
- Research Site - Lyon
- Research Site - Toulouse
- Research Site - Hamburg
- Research Site - Tübingen
Florida
- Research Site - Gainesville
Maryland
- Research Site - Rockville
Missouri
- Research Site - St Louis
New York
- Research Site - Commack
Ontario
- Research Site - Toronto
Quebec
- Research Site - Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 145 participants |
| Start Date | 2021-11-19 |
| Est. Completion | 2029-02-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04924608
The ClinicalTrials.gov registry entry for NCT04924608 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 145 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,029-participant average among 24 other Neurofibromatosis 1 trials with a reported enrollment target (86% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Neurofibromatosis 1 appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04924608 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Other, Florida, Maryland.
Frequently Asked Questions
What is clinical trial NCT04924608 about?
NCT04924608 is a clinical study titled "Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas". A global study to demonstrate the effectiveness of selumetinib in participants with NF1 who have symptomatic, inoperable plexiform neurofibromas.
What is the current status of trial NCT04924608?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 145 participants. The study started on 2021-11-19. Estimated completion is 2029-02-15.
What conditions does trial NCT04924608 study?
This clinical trial studies the following conditions: Neurofibromatosis 1, Plexiform Neurofibroma (PN).
What interventions are being tested in trial NCT04924608?
The interventions under investigation include: Placebo (OTHER), Selumetinib (DRUG).
Who is sponsoring clinical trial NCT04924608?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04924608 being conducted?
This trial has 20 study locations across Florida, Maryland, Missouri, New York, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neurofibromatosis 1
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Decentralized Clinical Trial to Promote Evidence-Based Care for Underserved Patients With Neurofibromatosis 1
RECRUITING · NA
-
Acceptance and Commitment Therapy for Caregivers of Children With a RASopathy: An Internal Pilot Feasibility Study and Follow-up Randomized Controlled Trial
RECRUITING · NA
-
Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (pNFs)
RECRUITING
-
A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia
RECRUITING · Phase 1
-
Tailoring an Online Platform to Promote Evidence-Based Care for Adults With Neurofibromatosis 1 and Low Health Literacy
RECRUITING · NA
-
Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.